Advertisement

Human Cell

, Volume 32, Issue 3, pp 360–366 | Cite as

Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer

  • Xiaoyou Li
  • Xia Zhao
  • Chenchen Li
  • Siwen Liu
  • Fei Yan
  • Yue Teng
  • Jifeng FengEmail author
  • Dengshun MiaoEmail author
Research Article
  • 45 Downloads

Abstract

Gefitinib is the first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), which is used in the treatment of NCSLC patients through interrupting EGFR signaling pathway. Although gefitinib prolongs patients’ progression-free survival (PFS), acquired resistance occurs in advanced NSCLC patients. In this study, we mainly investigated the effects of antagonist for ghrelin-R (d-lys-3-GHRP-6) on conquering acquired gefitinib resistance in human lung cancer cells. We found that GHSR was overexpressed in our established HCC827/GR cells compared with parental cells, accompanied with increase of p-AKT and p-ERK1/2. Treatment of d-lys-3-GHRP-6 significantly decreased p-AKT and p-ERK1/2 expression in HCC827/GR cells. H1650 cells and HCC827/GR cells were treated with control, gefitinib, d-lys-3-GHRP-6 and d-lys-3-GHRP-6 + gefitinib, respectively. In H1650 and HCC827/GR cells, combination of d-lys-3-GHRP-6 and gefitinib significantly inhibited cell proliferation and Bcl2 protein level, induced the cell apoptosis and cleaved-caspase3 protein level compared with control group, while there was no significant difference between control and gefitinib group.

Keywords

d-Lys-3-GHRP-6 Lung cancer Gefitinib-acquired resistance 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Carreras-Torres R, Johansson M, Haycock PC, et al. Obesity, metabolic factors and risk of different histological types of lung cancer: a Mendelian randomization study. Plos One. 2017;12:e0177875.CrossRefGoogle Scholar
  2. 2.
    Román M, Baraibar I, López I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17:33.CrossRefGoogle Scholar
  3. 3.
    Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017; 7:170070.CrossRefGoogle Scholar
  4. 4.
    Cheng WQ, Zheng RS, Zhang SW, et al. Analysis of Chinese lung cancer incidence and death from 2003 to 2007. J Pract Oncol. 2012;26:6–10.Google Scholar
  5. 5.
    Zheng YW, Li RM, Zhang XW, Ren XB. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest. 2013;31:197–205.CrossRefGoogle Scholar
  6. 6.
    Antonoff MB, D’Cunha J. Non-small cell lung cancer: the era of targeted therapy. Lung Cancer. 2012;3:31–41, 2012.Google Scholar
  7. 7.
    Zhang SR, Xu YS, Jin E, et al. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacol Sin. 2017;38:100–9.CrossRefGoogle Scholar
  8. 8.
    Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2014;20:5898–907.CrossRefGoogle Scholar
  9. 9.
    Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3:10–8.Google Scholar
  10. 10.
    Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. Plos Med. 2007;4:e315.CrossRefGoogle Scholar
  11. 11.
    Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated protein kinase RAS–RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103–19.CrossRefGoogle Scholar
  12. 12.
    Hu Y, Zang J, Cao H, et al. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro. Oncotarget. 2017;8:15802–14.Google Scholar
  13. 13.
    Seim I, Jeffery PL, Thomas PB, et al. Multi-species sequence comparison reveals conservation of ghrelin gene-derived splice variants encoding a truncated ghrelin peptide. Endocrine. 2016;52:609–17.CrossRefGoogle Scholar
  14. 14.
    Raghay K, Gallego R, Scoazec JY, Garcia-Caballero T, Morel G. Different ghrelin localisation in adult human and rat endocrine pancreas. Cell Tissue Res. 2013;352:487–94.CrossRefGoogle Scholar
  15. 15.
    Komarowska H, Jaskula M, Stangierski A, et al. Influence of ghrelin on energy balance and endocrine physiology. Neuro Endocrinol Lett. 2012;33:749–56.Google Scholar
  16. 16.
    Fujitsuka N, Asakawa A, Amitani H, Fujimiya M, Inui A. Ghrelin and gastrointestinal movement. Methods Enzymol. 2012;514:289–301.CrossRefGoogle Scholar
  17. 17.
    Rak-Mardyla A, Gregoraszczuk E. Effect of ghrelin on proliferation, apoptosis and secretion of progesterone and hCG in the placental JEG-3 cell line. Reprod Biol. 2010;10:159–65.CrossRefGoogle Scholar
  18. 18.
    Fung JN, Seim I, Wang D, et al. Expression and in vitro functions of the ghrelin axis in endometrial cancer. Horm Cancer. 2010;1:245–55.CrossRefGoogle Scholar
  19. 19.
    Yu H, Xu G, Fan X. The effect of ghrelin on cell proliferation in small intestinal IEC-6cells. Biomed Pharmacother. 2013;67:235–9.CrossRefGoogle Scholar
  20. 20.
    Nikolopoulos D, Theocharis S, Kouraklis G. Ghrelin: a potential therapeutic target for cancer. Regul Pept. 2010;163:7–17.CrossRefGoogle Scholar
  21. 21.
    Kui L, Weiwei Z, Ling L, et al. Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in adult rat cardiomyocytes through the PI3K–Akt signaling pathway. Regul Pept. 2009;155:62–9.CrossRefGoogle Scholar
  22. 22.
    Seim I, Jeffery PL, de Amorim L, et al. Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin. Reprod Biol Endocrinol. 2013;11:70.CrossRefGoogle Scholar
  23. 23.
    Terawaki K, Kashiwase Y, Sawada Y, et al. Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model. Plos One. 2017;12:e0173113.CrossRefGoogle Scholar
  24. 24.
    Gahete MD1, Córdoba-Chacón J, Hergueta-Redondo M, et al. A novel human ghrelin variant (In1-Ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. Plos One. 2011;6:e23302.CrossRefGoogle Scholar
  25. 25.
    Lin TC, Liu YP, Chan YC, et al. Ghrelin promotes renal cell carcinoma metastasis via snail activation and is associated with poor prognosis. J Pathol. 2015;237:50–61.CrossRefGoogle Scholar
  26. 26.
    Walter T, Chardon L, Hervieu V, et al. Major hyperghrelinemia in advanced well-differentiated neuroendocrine carcinomas: report of three cases. Eur J Endocrinol. 2009;161:639–45.CrossRefGoogle Scholar
  27. 27.
    Chen JH, Huang SM, Chen CC, et al. Ghrelin induces cell migration through GHS-R, CaMKII, AMPK, and NF-κB signaling pathway in glioma cells. J Cell Biochem. 2011;112:2931–41.CrossRefGoogle Scholar
  28. 28.
    Kuzumaki N, Suzuki A, Narita M, et al. Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming nonsmall-cell lung cancer. Plos One. 2012;7:e44368.CrossRefGoogle Scholar
  29. 29.
    Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–22.CrossRefGoogle Scholar
  30. 30.
    Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.CrossRefGoogle Scholar
  31. 31.
    Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9:52.CrossRefGoogle Scholar
  32. 32.
    Westphal M, Maire CL, Lamszus K. EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs. 2017;31:723–35.CrossRefGoogle Scholar
  33. 33.
    Zeng W, Zhu JF, Liu JY, Li YL, Dong X, Huang H, Shan L. miR-133b inhibits cell proliferation, migration and invasion of esophageal squamous cell carcinoma by targeting EGFR. Biomed Pharmacother. 2018;111:476–84.CrossRefGoogle Scholar
  34. 34.
    Song S, Jacobson KN, McDermott KM, et al. ATP promotes cell survival via regulation of cytosolic (Ca2+) and Bcl-2/Bax ratio in lung cancer cells. Am J Physiol Cell Physiol. 2016;310:C99–114.CrossRefGoogle Scholar
  35. 35.
    Wang DH, Hu JR, Wang LY, et al. The apoptotic function analysis of p53, Apaf1, Caspase 3 and Caspase7 during the spermatogenesis of the Chinese fire-bellied newt Cynops orientalis. Plos One. 2012;7:e39920.CrossRefGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyThe Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer ResearchNanjingChina
  2. 2.Department of Oncology, First People’s Hospital, Yancheng, Fourth Affiliated HospitalNantong UniversityYanchengChina
  3. 3.State Key Laboratory of Reproductive Medicine, The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and EmbryologyNanjing Medical UniversityNanjingChina

Personalised recommendations